AbbVie, facing thousands of lawsuits about its AndroGel testosterone supplement, notches a significant win
AbbVie notched a win late last month in its ongoing battle against thousands of lawsuits that claim AndroGel, a once-blockbuster drug marketed to treat low testosterone in men, causes heart attacks, strokes and other injuries.
A jury decided the North Chicago-based drugmaker was not to blame for...